Panacea Biotec Limited

BSE:531349 Stock Report

Market Cap: ₹26.1b

Panacea Biotec Past Earnings Performance

Past criteria checks 0/6

Panacea Biotec has been growing earnings at an average annual rate of 20.3%, while the Biotechs industry saw earnings growing at 9.7% annually. Revenues have been declining at an average rate of 1.7% per year.

Key information

20.3%

Earnings growth rate

20.4%

EPS growth rate

Biotechs Industry Growth5.1%
Revenue growth rate-1.7%
Return on equity-1.9%
Net Margin-2.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Panacea Biotec makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:531349 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245,500-1471,7170
30 Jun 245,457-2791,5110
31 Mar 245,592-121,6430
31 Dec 235,516-1171,6350
30 Sep 235,163991,5790
30 Jun 234,7843341,3040
31 Mar 234,599-3321,5170
31 Dec 224,71812,1641,6920
30 Sep 225,12411,4781,8280
30 Jun 226,39510,7911,7060
31 Mar 226,61210,7832,0500
31 Dec 216,888-2,1372,0140
30 Sep 216,746-2,0461,9490
30 Jun 216,245-1,7041,6550
31 Mar 216,248-1,4621,7740
31 Dec 205,819-1,6041,7240
30 Sep 206,079-1,4051,4740
30 Jun 205,510-1,9451,4530
31 Mar 205,441-1,8781,6490
31 Dec 195,4546531,5730
30 Sep 194,8807151,5210
30 Jun 194,8324821,3960
31 Mar 194,5674101,6200
31 Mar 185,928-7161,7120
31 Mar 175,440-3921,7970
31 Mar 166,531-1831,7080
31 Mar 156,872-1,0651,6680
31 Mar 145,100-1,1212,6610

Quality Earnings: 531349 is currently unprofitable.

Growing Profit Margin: 531349 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 531349 is unprofitable, but has reduced losses over the past 5 years at a rate of 20.3% per year.

Accelerating Growth: Unable to compare 531349's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 531349 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).


Return on Equity

High ROE: 531349 has a negative Return on Equity (-1.85%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies